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Abstract
In this study, a data-dependent, high-resolution tandem mass spectrometry (ddHRMS/MS) method 
capable of detecting all organophosphorus nerve agent (OPNA) adducts to human 
butyrylcholinesterase (BChE) was developed. After an exposure event, immunoprecipitation from 
blood with a BChE-specific antibody and digestion with pepsin produces a nine amino acid 
peptide containing the OPNA adduct. Signature product ions of this peptic BChE nonapeptide 
(FGES*AGAAS) offer a route to broadly screen for OPNA exposure. Taking this approach on an 
HRMS instrument identifies biomarkers, including unknowns, with high mass accuracy. Using a 
set of pooled human sera exposed to OPNAs as quality control (QC) materials, the developed 
method successfully identified precursor ions with <1 ppm and tied them to signature product ions 
with <5 ppm deviation from their chemical formulas. This high mass accuracy data from precursor 
and product ions, collected over 23 independent immunoprecipitation preparations, established 
method operating limits. QC data and experiments with 14 synthetic reference peptides indicated 
that reliable qualitative identification of biomarkers was possible for analytes >15 ng/mL. The 
developed method was applied to a convenience set of 96 unexposed serum samples and a blinded 
set of 80 samples treated with OPNAs. OPNA biomarkers were not observed in convenience set 
samples and no false positive or negative identifications were observed in blinded samples. All 
biomarkers in the blinded serum set >15 ng/mL were correctly identified. For the first time, this 
study reports a ddHRMS/MS method capable of complementing existing quantitative 
methodologies and suitable for identifying exposure to unknown organophosphorus agents.
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Introduction
Organophosphorus nerve agents (OPNAs)1,2 are a class of internationally-banned chemical 
warfare agents that broadly target a family of enzymes known as serine hydrolases.3 OPNAs 
disable serine hydrolases by phosphorylating their active site serine residues. Since OPNAs 
have such broad inhibitory activity, many different combinations of ligands retain potent 
activity. Therefore, over a thousand4 distinct species of OPNA structures have been defined 
as schedule 1 agents by the Chemical Weapons Convention.5
Inhibition of acetylcholinesterase (AChE) in the nervous system by OPNAs is responsible 
for producing a number of characteristic toxic effects including seizures and associated 
motor convulsions. AChE inhibition leads to accumulation of acetylcholine in synapses and 
a loss of signal transmission.2 Traditionally, inhibition of AChE was detected using the 
Ellman activity assay which measures choline production as a measure of enzyme activity.6 
This assay has been widely used for clinical assays, such as the detection of 
organophosphorus (OP) pesticide exposure.7 While effective, activity-based assays cannot 
identify a specific agent in an exposure event. Hydrolyzed OPNA metabolites identify 
metabolites of specific agents from urine or blood;8,9 however, these metabolites are short-
lived, and the majority of excretion occurs days after an exposure has occurred.10,11 
Analysis of OPNA adducts to albumin offer another route to verify exposure.12 However, 
albumin poorly reacts with V-series agents, limiting its application.
OPNAs also inhibit a related, more accessible enzyme from blood known as 
butyrylcholinesterase (BChE).13 The relative abundance and longevity of BChE in blood 
makes it an ideal biomarker to assess OPNA exposure weeks after an exposure event.14 
BChE activity assays, similar to the Ellman assay, measure choline turnover but still cannot 
identify a specific causative agent.15,16 Fluoride reactivation assays, developed after a sarin 
attack in a Tokyo subway in the late 1990s, were a major leap forward in post-exposure 
OPNA detection.17 Typically, these assays utilize a nucleophilic fluoride anion to regenerate 
the specific nerve agent for GC-MS analysis from blood, identifying the specific agent 
used.18
Perhaps the most effective BChE-based detection methods center on UHPLC-MS/MS 
analysis of digest products. After immunoprecipitation of the enzyme from blood, BChE is 
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digested with pepsin to produce a nine amino acid peptide (FGES*AGAAS, nonapeptide) 
which contains the covalently-bound nerve agent for analysis.19,20,21,22 However, in addition 
to their numerous structural combinations, many OPNAs undergo dealkylation after binding 
to BChE (Figure 1),23 a process known as aging, which creates more potential biomarkers 
for analysis. Currently, all OPNA-BChE biomarkers must be targeted by quantitative assays 
to confirm exposure events. Supporting such a large number of targeted methods places a 
large burden on the public health laboratories responsible for assessing OPNA exposure.
While OPNAs have many structural combinations, product ions formed by the BChE 
nonapeptide under MS/MS conditions do not retain the specific OPNA adduct. Therefore, 
the same products ions are always observed regardless of which OPNA is bound.24,25,26 
These conserved product ions are signature b-ions (containing the nonapeptide amino 
terminus after loss of the OPNA adduct)27 that can be broadly used by qualitative screening 
assays to determine OPNA exposure regardless of the initial precursor ion mass. For 
example, a blood sample taken from an exposed individual days after an exposure event may 
contain several distinct biomarkers of OPNA exposure, which requires complicated targeted 
analysis.28,29 A BChE-based screening method could determine the presence of multiple 
biomarkers by identifying the signature b-ions that are uniformly generated. Given the large 
number of possible OPNAs, an exposure to an unknown OPNA may also occur. In this case, 
a targeted method would not detect exposure because the precursor ion mass-to-charge ratio 
(m/z) would be unknown. Previous studies used product ion scans in methods with 
conventional triple quadrupole instruments to screen for exposure.30 However, their targeted 
design and low resolving power limited identification to only anticipated precursor ions.
Proteomics offers an efficient route to screen for characteristic BChE nonapeptide product 
ions. Data-dependent high-resolution tandem mass spectrometry (ddHRMS/MS) methods, 
most often used to sequence peptides, collect data in two distinct layers. First, the instrument 
acquires a full mass spectrum with high resolving power and identifies the most intense ions 
in that scan. Next, the instrument selects the most intense ions for dissociation, collecting 
high-resolution spectra on the product ions generated and tying them to specific precursor 
ions.31 Applying this analytical strategy to the OPNA-adducted nonapeptide would provide 
an effective route to screen for OPNA-BChE biomarkers by their signature b-ions and 
identify precursor ions with high mass accuracy. Ideally, this method would complement 
existing targeted methodologies using the same preparation, vastly increasing laboratory 
efficiency.
For the first time, this study describes the development, characterization, and validation of a 
BChE screening method capable of identifying unknown OPNA adducts to BChE through 
the analysis of signature product ions by UHPLC-ddHRMS/MS. High mass accuracy was 
observed across 23 independent quality control (QC) preparations of human plasma exposed 
to various OPNAs. Using these samples for characterization, precursor ions were identified 
with a mean mass accuracy of <1 ppm while signature BChE nonapeptide product ions were 
identified with a mean mass accuracy of <5 ppm. In addition to QC preparation, a set of 14 
synthetic BChE biomarker peptides, representing both aged and unaged OPNA adducts, 
were analyzed and used to establish reliable qualitative identification of analytes above 15 
ng/mL. Method validation focused on two sets of experiments. First, the method analyzed a 
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set of 96 individual presumably unexposed human plasma samples. All samples from this set 
yielded data consistent with a lack of OPNA exposure. The method also analyzed a blinded 
set of 80 serum samples treated with OPNAs. All biomarkers above 15 ng/mL were 
identified with a 100% success rate. Importantly, the method did not identify any false 
positives or false negatives in these samples. This method complements existing quantitative 
methods and increases confidence in exposure verification. More importantly, the work 
herein describes the first OPNA-BChE screening method capable of identifying exposure to 
an unknown OPNA.
Materials and Methods
Materials
HPLC-grade acetonitrile and water were obtained from Fisher Scientific (Waltham, MA). 
Tween-20, trimethylamine (TEA) buffer, phosphate buffered saline, dimethyl pimelimidate 
dihydrochloride and tris-buffered saline were obtained from Sigma-Aldrich (St. Louis, Mo). 
Dynabeads for immunomagnetic separation of BChE from blood products were obtained 
from Life Technologies (ThermoFisher Scientific, Grand Island, NY). King Fisher deep well 
plates, shallow well plates, and tip combs, protein precipitation plates, heat sealing foil, and 
96-well autosampler plates were all obtained from Fisher Scientific (Waltham, MA). 
Synthetic peptides were used throughout this study for method optimization and 
isotopically-labeled peptides were used as internal standards. BChE, GB-BChE, P-BChE, 
VX-BChE, VR-BChE, and oCP-BChE synthetic peptides were supplied by The Netherlands 
Organisation for Applied Scientific Research (TNO; Rijswijk, Netherlands). Synthetic 
peptides for GE-BChE, GD-BChE, GF-BChE, PrP-BChE, PrGB-BChE, MeP-BChE, ExP-
BChE, and EtP-BChE were obtained from Battelle Memorial Institute (Columbus, OH). As 
detailed in a previous publication, the following abbreviations were used for OPNA-BChE 
biomarkers: BChE – butyrylcholinesterase; P-BChE – phosphorylated BChE; MeP-BChE – 
methyl phosphonate-adducted BChE; EtP-BChE – Ethyl phosphonate-adducted BChE; ExP-
BChE – Ethoxy-phosphoryl butyrylcholinesterase; Propyl-BChE – propyl phosphonate-
adducted BChE; VX-BChE – VX- adducted BChE; GB-BChE – Sarin-adducted BChE; GE-
BChE – Ethyl Sarin-adducted BChE; VR-BChE – Russian VX-adducted BChE; oCP-BChE 
– ortho-cresylphosphate-adducted BChE; GF-BChE – Cyclosarin-adducted BChE; GD-
BChE – Soman-adducted BChE..27 Isotopically-labeled and native peptides were matched 
from the same vendor. For example, native and isotopically-labeled BChE nonapeptide were 
both supplied by TNO.
Preparation of Quality Control (QC) Materials
Pooled human plasma (QC low, QCL) and plasma whose BChE was fully inhibited with GB 
(QC high, QCH) were obtained from Battelle Memorial Institute (Columbus, OH). Plasma 
was deemed fully inhibited by GB according to a loss of BChE enzyme activity. To prepare 
the methyl phosphonate adduct in plasma (QC mid, QCM), plasma fully inhibited by GB 
was incubated at 37°C for 17 days. BChE-free matrix blank was prepared by filtering 
pooled, untreated human plasma through a 10 kDa centrifugation filter (Millipore; Bellerica, 
MA). All QC materials were divided into 1 mL aliquots and stored at −70°C until needed for 
each assay.
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Sample Preparation
Immunomagnetic isolation of BChE has been described previously.27 The BChE 
monoclonal antibody (BioPorto, Hellerup, Denmark; clone ID 3E8) was conjugated to 
Protein G-coated DynaBeads (ThermoFisher Scientific, Grand Island, NY). Preparation of 
the beads began by aliquoting 2mL of beads and washing them with two-4 mL volumes of 
phosphate buffered saline containing Tween-20. Beads were next suspended in 8 mL of PBS 
Tween-20, and 400 μg of BChE antibody was added. Beads were rotated overnight (16 h) at 
room temperature. After incubation, the PBS Tween-20/antibody mixture was removed, and 
beads were washed with two volumes of triethanolamine (TEA) buffer (Sigma-Aldrich; St. 
Louis, IL). Beads were then incubated for 30 min in a 5.4 mg/mL solution of dimethyl 
pimelimidate in TEA buffer at room temperature. Supernatant was removed, and the beads 
were washed with 4 mL of PBS Tween-20. Beads were incubated again with 4 mL of TBS at 
room temperature for 15 min. Beads were washed two additional times in 2 mL volumes of 
PBS Tween-20 and re-suspended in 1.9 mL of PBS Tween-20. Beads were stored in this 
solution at 4°C until use.
For QC and sample analysis, 125 μL of each sample was thawed and filtered through a 96-
well 0.45 μm PVDF filter plate (Millipore; Bellerica, MA) and centrifuged at 3000 xg for 5 
min. After this time, samples were transferred to a 96-deep-well plate, and magnetic beads 
were added using a Thermo Scientific KingFisher (Waltham, MA) liquid handling system. 
The bead-plasma suspension was shaken at 1400 RPM for 45 min. While shaking, a 
digestion plate was prepared by adding 75 μL of 0.6% formic acid to a 96-well plate 
followed by 10 μL of 2 mg/mL solution of pepsin also in 0.6% formic acid. A 10 μL volume 
of a 500 ppb solution of isotopically-labeled synthetic peptides (Battelle Memorial Institute 
and TNO) may also be added to this mixture (to verify injection and proper instrument 
function) and will not interfere with unknown identification. After incubation was complete, 
beads loaded with BChE were washed three times with PBS-tween and transferred to the 
digestion solution via the KingFisher. Beads were incubated at 37°C for 30 min and shaken 
for one minute intervals at 1000 RPM for 10 seconds. After incubation, the KingFisher was 
used to remove the beads from the digestion solution. The remaining digestion solution was 
mixed with 285 μL of acetonitrile to precipitate any remaining whole proteins and filtered 
through a protein precipitation plate (ThermoFisher Scientific, Waltham, MA) under 
vacuum. The eluent was then dried under a stream of nitrogen for 45 min. Samples were re-
suspended in 0.6% formic acid and transferred to an Eppendorf 96-well PCR plate 
(Hauppauge, NY) for analysis.
UHPLC-ddHRMS/MS
For chromatographic resolution and separation of known analytes from matrix background, 
an Agilent 1290-series UHPLC system (Agilent Technologies, Santa Clara, CA) was 
equipped with a Phenomenex Kinetex Biphenyl 50 × 2.1 mm, 1.7μm, 100Å pore size 
column (Phenomenex, Torrance, CA). Mobile phase A was water with 0.1% formic acid, 
and mobile phase B was acetonitrile with 0.1% formic acid. The following gradient was 
used at a constant flow rate of 0.1 mL/min: 0 to 5 min, 2% B; from 5 to 35 min, B was 
linearly increased from 2% to 18%; from 35 to 50 min, B was linearly increased from 18% 
to 40%; from 50 to 50.1 min, B was increased to 90% and held until 55 min; after this time, 
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B was immediately taken back to 2% and the column was equilibrated for 5 min. For each 
analysis, the column temperature was kept at 60°C, and 10 μL of sample was injected. The 
autosampler compartment was set to 8°C, and the injection needle was washed for 20 
seconds with a 10% solution of methanol in water.
Data-dependent acquisition was achieved with a Thermo Scientific QExactive mass 
spectrometer (ThermoFisher Scientific, Waltham, MA) set to ddMS2/SIM mode. Every 48 
hours, the instrument performance was evaluated and calibrated using Thermo Scientific 
CalMix calibration solution. Parameters that fell out of control according to CalMix 
evaluation were also calibrated. Prior to analysis of QC samples, a purified mixture of native 
synthetic peptides in 0.6% formic acid (at 32 ppb) was injected to ensure mass accuracy and 
that data-dependent isolation and dissociation of ions was working optimally.
Data Acquisition and Processing
MS1 and MS2 spectra were stored on the instrument as data was collected. Instrument data 
sets were initially analyzed using Thermo Scientific QualBrowser version 3.1.66.10 using a 
mass range filter set to search for characteristic phosphate adducted BChE nonapeptide 
product ions (m/z 778.3366, m/z 673.2940 and m/z 602.2569) with a 10 ppm tolerance. 
Final analysis was conducted with the TraceFinder 3.2 software (ThermoFisher Scientific, 
Waltham, MA) set to screening mode. In this mode, the software can identify high mass 
accuracy product ions and precursor ions from both QC materials and unknowns. For data 
analysis of QC materials, a compound library was created based on precursor and product 
ion masses of those found in GB-inhibited pooled plasma, fully aged GB-inhibited pooled 
plasma, and uninhibited plasma. Data gathered on unknowns was first analyzed using 
QualBrowser as described above. Precursor ions identified were used to build custom 
libraries for unknown samples and analyzed in the blinded study. High resolution masses of 
unknowns and QC materials are exported from TraceFinder as a Microsoft Excel file for 
statistical analysis.
Convenience Set and Unknown Exposure Analysis
A convenience set of 96 individual human serum samples was obtained from Tennessee 
Blood Services (Tennessee Blood Services Corporation, Memphis, TN). The method used 
blood products acquired from commercial sources, and the work did not meet the definition 
of human subjects as specified in 45 CFR 46.102(f). Samples were prepared as described 
above, and data analysis was completed using both QualBrowser and TraceFinder. Data 
were exported and analyzed to establish a mean m/z value and standard deviation.
A blinded set of 80 spiked samples were prepared and analyzed as described above. 
Unknown mass values were recorded and exported as high accuracy m/z values using 
TraceFinder. Data were then scored using the identities of each blinded sample in order to 
calculate a percent positive identification.
Safety Considerations
Appropriate safety control measures, including engineering, administrative, and personal 
protective equipment, were used for all procedures based on a site-specific risk assessment 
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that identified physical, health, and procedural hazards. OPNA-spiked serum or plasma was 
evaluated prior to receipt to ensure all live agent was quenched. Serum and plasma evaluated 
in this way present no additional risks outside of those present when working with human 
blood products. Additionally, all blood products are screened for potential blood borne 
pathogens prior to receipt. Universal precautions for working with these materials should be 
followed while using this method.
Results and Discussion
Method Development and Optimization
The proteomics literature31 offers a route to reliably screen for signature product ions of 
adducted BChE nonapeptides. Known as data-dependent acquisition, this specific scan mode 
is regularly used to sequence and identify peptides present in a sample. Data-dependent 
acquisition first identifies the most intense ions in a precursor ion scan. Next, the instrument 
selects these ions for fragmentation in real time and collects product ion spectra on each 
before conducting another full scan to complete the duty cycle. Data-dependent acquisition 
constantly records and links together precursor and product ion spectra. Therefore, applying 
this instrument logic to BChE nonapeptide analysis on a high resolution instrument would 
provide high-confidence identification of characteristic product ions. This scan mode would 
also provide chemical formulation of unknown precursors that produce the characteristic 
fragment ions. Accurate mass data collected in the assay can serve as a reporting metric and 
provide limits of mass accuracy for both QC materials and product ion masses of unknowns. 
With these considerations in mind, a basic data collection and QC metric was envisioned for 
development on a QExactive mass spectrometer (Figure 2).
Reliable data-dependent selection of the BChE nonapeptide between samples was the first 
critical consideration for the method’s success. Since data-dependent acquisition relies on 
the identification of abundant peaks in a precursor ion scan, enrichment of the BChE 
nonapeptide was necessary. Current OPNA-BChE detection methods developed within our 
laboratory rely heavily on the immunomagnetic separation of BChE from human blood 
products.27 This approach decreases sample complexity and ensures high fidelity data-
dependent identification of analytes between samples. The conservation of a single sample 
preparation between multiple methods has the added benefit of increasing laboratory 
efficiency and decreasing costs since a single preparation may be used for several different 
analytical tests.
Instrument method development began by optimizing source parameters and collision 
energies on synthetic BChE nonapeptides to produce the characteristic product ions for 
identification. Using these peptides, a normalized collision energy (NCE) of 22% induced 
regular dissociation patterns among potential analytes. Figure 3 shows the dissociation 
patterns optimized and observed for this method. These spectra represent product ions of the 
nonapeptides generated from untreated plasma (BChE nonapeptide), plasma treated with GB 
(GB-BChE), and aged GB-treated plasma, which hydrolyzes to the methyl phosphonate 
adduct to BChE (MeP-BChE). After optimization, the method reliably generated all 
characteristic BChE nonapeptide product ions with mass accuracies of 5 ppm or less.
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Data-dependent acquisition on the QExactive mass spectrometer requires careful 
optimization of resolving power, trap fill times, and dynamic exclusion to balance 
sensitivity, accuracy, and reproducibility. While these parameters affect spectral quality and 
sensitivity, they also affect duty cycle times. Longer duty cycles are potentially problematic 
since they may result in the loss of analyte selection for fragmentation in a data-dependent 
assay. Duty cycle times were therefore carefully considered throughout instrument method 
optimization.
Prior to introduction into the orbitrap for mass analysis, ions are collected in a transient, 
curved ion trap, termed the c-trap. Maximum injection times (maximum IT) into the c-trap 
can be extended to boost sensitivity within a method. While longer trap fill times increase 
sensitivity, they also lengthen instrument duty cycles times. Maximum IT works with the 
automatic gain control (AGC) target to set a maximum threshold of ions collected in the c-
trap. Thus, c-trap fill times vary throughout a method based on ion abundance. Finally, the 
underfill ratio was set to 1%, bringing the intensity threshold to a value of 1.3×103 cps. 
Working with the AGC target value, the underfill ratio dictates a minimum ion intensity for 
ddHRMS/MS selection. The set value for this method is quite low. However, the high 
sample purity obtained after BChE immunomagnetic precipitation significantly decreases 
potential interference from the sample matrix. Thus, having a low intensity threshold 
increases the likelihood of BChE nonapeptide selection without the potential of matrix 
interference.
High resolution mass analysis takes place in the QExactive’s orbitrap mass analyzer. In the 
orbitrap, resolving power directly correlates with scan times and is defined as the separation 
of ions at a given m/z. Since peak width is essential for resolution in a mass spectrum, 
resolving power is defined as full width at half maximum (FWHM). To properly balance 
duty cycle times and analyte separation from matrix background, full scan resolution was set 
to 70,000 FWHM and product ion scan to 17,500 FWHM. These values provided optimal 
peak resolution from matrix background while keeping duty cycles as low as possible. A 
high fidelity data-dependent acquisition method was developed by carefully balancing these 
specific parameters and others. A more detailed list of optimized method parameters can be 
found in the supplemental information.
Despite the high sample purity after immunomagenetic separation of BChE from blood 
products, method chromatography was also optimized to further separate analytes from 
matrix background and ensure high fidelity data-dependent analysis. A 60 minute binary 
gradient of water and acetonitrile with 0.1% formic acid provided ideal peak shape and 
separation of known nonapeptides from matrix background. As a measure of 
chromatographic performance, a mixture of synthetic BChE nonapeptides were analyzed 
(Figure 4). The mixture evaluated in this experiment consisted of both unaged adducts and 
aged adducts to BChE, representative of potential findings following an OPNA exposure. 
The synthetic peptides used for this experiment were present at 32 ng/mL. In general, more 
polar unadducted and aged BChE species eluted earlier in the chromatographic gradient. The 
more hydrophobic unaged biomarkers required a higher percentage of organic solvent for 
elution. Despite the shallow gradient, some peaks still co-eluted, such as EtP-BChE and 
ExP-BChE. No challenges were encountered in distinguishing their data-dependent 
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identification given the significant mass differences of these co-eluting species. Some 
nonapeptide biomarkers shared identical chemical compositions, such as PrP-BChE and 
VX-BChE, but were resolved chromatographically. These results suggested that 
ddHRMS/MS and UHPLC parameters were sufficiently optimized to identify all potential 
OPNA adducts.
As a final measure of method performance prior to characterization, synthetic BChE 
nonapeptides were analyzed at specific concentrations of 2, 4, 8, 16, 32, 64, and 125 ng/mL. 
These peptide mixtures included G- and V- series nonapeptides. This set also included 
nonapeptides with poor ionization corresponding to unadducted BChE nonapeptide, P-
BChE, and oCP-BChE. Therefore, this set of analytes is highly representative of the range of 
biomarkers likely to be observed after an OPNA exposure event. These peptide pools were 
examined in a matrix background at each concentration to establish a range of method 
performance. Method performance was considered good when reproducible data-dependent 
selection and fragmentation of peptides was observed. At concentrations below 15 ng/mL, 
the characteristic BChE fragment ions of OPNA-BChE biomarkers were not reproducibly 
observed for all analytes. Therefore, the method was considered to have good performance 
for biomarker identification at concentrations above 15 ng/mL. Analysis of convenience set 
samples in a previous study found that the human BChE nonapeptide has an average 
concentration of 40 ng/mL after immunoprecipitation.24 Therefore, biomarker values at or 
above the threshold of 15 ng/mL are reasonable to expect after an exposure incident.
Method Validation
Qualitative method validation focused on three specific areas: data-dependent dissociation of 
analytes, product ion mass accuracy, and precursor ion mass accuracy. With these 
parameters in mind, human plasma treated with OPNAs served as the best possible QC 
material to assess method performance since it would provide all possible matrix effects 
from clinical samples during characterization. Orbitrap m/z resolving power varies with ion 
mass,32,33 so OPNA-treated plasma samples were chosen based on a range of potential 
biomarker masses. QCL for this method was pooled human plasma which only yielded the 
unadducted BChE nonapeptide after work up (m/z 796.3472) while QCH is pooled human 
plasma fully inhibited with GB yielding the GB-BChE nonapeptide after preparation (m/z 
916.3812). Finally, QCM was pooled human plasma fully inhibited with GB and aged for 
three weeks at 37 °C. This QC yields the aged product, MeP-BChE, after work up (m/z 
874.3342). Human BChE exists as a glycosylated homotetramer of four 100 kDa subunits in 
blood,34 so a matrix blank of human plasma prepared by 10 kDa MWCO filtration was 
chosen and shown to produce no detectable BChE nonapeptide product ions. Using these 
QC materials and matrix blank, four separate analysts prepared and collected data on 23 
independent sets of QC materials over the course of four weeks. No more than two QC sets 
were acquired each day,35 and the high mass accuracy data was exported into an Excel 
spreadsheet for upload into a data management (STARLIMS) system equipped with 
statistical analysis software (SAS, Carey, NC).
BChE nonapeptides from QCL, QCM, and QCH lots were reproducibly selected for 
dissociation across all 23 preparations and produced the three signature product ions 
Mathews et al. Page 9
Anal Chem. Author manuscript; available in PMC 2018 February 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
consistently. After selection and dissociation, product ions were reliably identified with high 
mass accuracy (< 5 ppm standard deviation in mass from the mean) (Table 1). Acquiring QC 
precursor ion masses at a higher resolving power (70,000 FWHM) provided a mass 
measurement with < 1 ppm deviation across 23 QC sets (Table 2). Thus, when analytes were 
present at a concentration of > 15 ng/mL, the method reliably identified biomarkers with 
high confidence. The high mass accuracy and precision observed in the validation data 
highlights the strength of this method when analyzing clinical samples exposed to a 
potentially unknown OPNA. Additionally, the mass accuracy serves as an ideal complement 
to existing quantitative assays of OPNA exposure – providing more confidence in reporting 
an exposure event. The mass accuracy limits established from method characterization data 
by the SAS calculation provided limits of mass variance for OPNA-BChE nonapeptide in 
QC materials. These limits serve as a guide for method performance between samples sets 
and establish criteria for reporting data in the case of an exposure event.
Method Stability and Ruggedness
Previous characterization and validation studies performed on related BChE adduct methods 
detailed material stability and digestion conditions.24,36 For this study, the parameters most 
critical to method performance, specifically data-dependent selection of BChE nonapeptides 
were identified and tested to establish method limitations and ruggedness. Separation of 
OPNA analytes from matrix background was a major factor for method performance in 
characterization, so initial solvent composition, UHPLC gradient slopes, and flow rates were 
varied. Changes in these parameters only had a slight impact on performance which varied 
between analytes (see supplemental information for details).
Since the method relies on the accurate identification of fragment ion masses for assessment 
of exposure, fragmentation energies and HRMS mass calibration were varied to establish 
their effect on method performance. Collision energies were varied by 10% and exhibited 
only modest impacts on analyte identification. Finally, high mass accuracy was left 
uncalibrated for 12 days and showed no significant impact on method performance. Taken 
together, these results suggest this method is stable and amenable to use in clinical 
laboratories using defined limits for data reporting. Additional details of ruggedness 
evaluation can be found in the supplemental information.
96 Individual Matrix Sample Convenience Set
Pooled human plasma was used throughout method characterization; however, the method is 
expected to test for exposure in individuals. Therefore, a commercial convenience set of 96 
individual, presumably unexposed samples was used to establish how reproducibly signature 
product ions were observed in individuals. Importantly, mutations to the BChE nonapeptide 
detected in this method occur at extremely low rates, < 0.01%,37,38 and should have a 
minimal impact on this method. The acquired precursor and product ion spectra of the BChE 
nonapeptide from all 96 patient samples showed no significant (< 5 ppm) mass deviation 
between individuals (Figure 5). Furthermore, no spectra yielded a precursor ion indicative of 
OPNA exposure, and all 96 individual samples yielded the precursor ion expected for BChE 
nonapeptide with < 1 ppm deviation in mass accuracy.
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Theoretically, methods broadly screening for OPNA adducts to BChE have the capability to 
detect exposure to organophosphorus (OP) pesticides. Indeed, previously developed methods 
using low resolution instruments projected the presence of low levels of OP pesticide 
exposure.16,39 Of the 96 individual serum samples evaluated in our convenience set, none 
possessed biomarkers consistent with OP pesticide exposure, possibly due to either the size 
of the convenience set or the method’s current lowest reportable limit.
80 unknown exposure samples
As a final validation of method performance, a set of 80 blinded samples was analyzed to 
simulate those that may be received in a suspected exposure event. To ensure optimal 
method performance and sample preparation, the 80 blinded samples were split into four 
batches of 20 samples, each batch analyzed alongside a QC characterization set. The analyst 
prepared and analyzed the blinded samples and QC sets according to the established method 
protocol. In a suspected exposure event, a variety of OPNA-BChE biomarkers may be 
observed at different concentrations. Unknown, agent-spiked plasma sample specimens 
analyzed in this experiment also contained a variety of different biomarkers at the 
concentrations anticipated in a suspected exposure event. This set also included samples 
where only a fraction of BChE was inhibited. Unexposed samples were also included in the 
set to further assess the rate of false positive identifications. The comparison of the 
theoretical value versus experimentally-determined value was used to score the method’s 
performance. The results of these blinded sets and the total number biomarkers present 
versus those identified can be found in Table 3.
TraceFinder identifies mass features using a custom reference library. Libraries in 
TraceFinder are easily editable to add new or unknown analytes. For the purposes of this 
blinded study, the analyst updated a reference library based on the positive identification of 
key product ion masses (m/z 602.2569, 673.2940 and 778.3366) from ddHRMS/MS spectra.
The 80 unknown specimens were a combination of individual unexposed serum, serum 
exposed to one agent, serum exposed to multiple agents, aged serum, and other human 
matrices such as urine. Analytes present above the established performance limit of 15 
ng/mL were correctly identified in every sample. Some unknown samples were mixtures of 
multiple pooled human serum samples exposed to different individual agents. These 
mixtures resulted in a 6 to 1 dilution of the anticipated analytes, below the method’s 
performance limit. In addition to the method’s 100% success rate, no false positive or 
negative identifications were observed. The results collected in this final evaluation of 
method performance demonstrate how this method significantly increases the number of 
observable analytes within a single method while maintaining a high level of accuracy and 
precision.
Conclusions
This study presents a new tool for public health investigators to screen for more potential 
biomarkers after an OPNA exposure event. The developed method centers on the 
identification of signature product ions of the BChE nonapeptide which are produced after 
exposure to OPNAs. Since specific OPNA-BChE analytes are not targeted by this method, 
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every possible OPNA-BChE nonapeptide biomarker can be screened in a single analytical 
run. This method reliably identified biomarkers with extremely high mass accuracy by their 
signature product ions throughout characterization. When this method was applied to a set of 
80 potentially exposed samples, it identified 100% of the biomarkers within its reportable 
range. A commercial convenience set determined less than 1% false positive identification 
rate of OPNA-BChE biomarkers for this test. This method is currently employed within our 
laboratory alongside a targeted assay for high-priority OPNA-BChE nonapeptide 
biomarkers. The data generated by this qualitative method complements our targeted assay 
to increase confidence in biomarker identification and catch any potential unknown OPNA-
BChE biomarker. Currently, this method is not suitable for high-throughput screening. 
However, we plan to continue improving future versions of this method by increasing 
analyte sensitivity for detection below 15 ng/mL and decreasing analytical run times.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Adduction mechanism of OPNAs to BChE
OPNAs inhibit their target serine hydrolases (SHs), such as BChE, by covalently binding to 
the active site serine. Aging of OPNA adducts occurs in blood whereby alkyl-phosphate 
variable groups (blue) on the OPNA adduct are non-specifically hydrolyzed to the 
corresponding phosphonic or phosphoric acid while the alkyl-phosphonate variable groups 
(red) remain unchanged. OPCW-CWC nomenclature defines R1 as a variable alkyl group 
(i.e. ethyl, methyl, propyl, or cyclohexyl) or a hydroxyl group; R2 can be either a variable 
alkyl group or an amino alkyl group.
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Figure 2. Data dependent BChE method workflow
Data-dependent analysis of peptides begins with a survey of the most abundant ions in a 
precursor ion scan. These ions are then selected for fragmentation in real time by the 
instrument. After data-dependent acquisition of a BChE peptic digest, product ion scans are 
searched for characteristic product ions of the BChE nonapeptide. These product ions are 
linked to the precursor scans where an abundant analyte was first identified. After 
acquisition and recording, these high mass accuracy values are statistically analyzed for 
external reporting.
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Figure 3. Principles and verification of ddHRMS/MS method development for unadducted 
BChE and adducted BChE biomarkers
After the immunoprecipitation of the BChE protein from blood, serum or plasma and 
digestion with pepsin, the resulting BChE nonapeptide produces signature product ions upon 
collision-induced dissociation. These product ion masses correspond to cleavages along the 
peptide backbone (b7 and b8) and β-elimination ions from serine 198. These losses happen 
at different rates depending on phosphorylation. Product ions identified from representative 
ddHRMS/MS spectra are shown alongside their theoretical masses and cleavages from the 
specific nonapeptide structures (highlighted in blue, green, and orange).
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Figure 4. Extracted ion chromatogram of possible analytes following OPNA exposure
A mixture of synthetic peptides used in targeted methods following OPNA exposure were 
examined using the UHPLC-ddHRMS/MS method. Mass deviation of precursor ion species 
from theoretical was less than 10 ppm. Abbreviations: BChE – butyrylcholinesterase; P-
BChE – phosphorylated BChE; MeP-BChE – methyl phosphonate-adducted BChE; EtP-
BChE – Ethyl phosphonate-adducted BChE; ExP-BChE – Ethoxy-phosphoryl 
butyrylcholinesterase; Propyl-BChE – propyl phosphonate-adducted BChE; VX-BChE – 
VX- adducted BChE; GB-BChE – Sarin-adducted BChE; GE-BChE – Ethyl Sarin-adducted 
BChE; VR-BChE – Russian VX-adducted BChE; oCP-BChE – ortho-cresylphosphate-
adducted BChE; GF-BChE – Cyclosarin-adducted BChE; GD-BChE – Soman-adducted 
BChE.
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Figure 5. Identification of unadducted BChE nonapeptide ions from a convenience set of 96 
individual matrix samples
Analysis of 96 individual, presumably unexposed serum samples was performed. All 96 
samples produced signature product ions consistent with the unadducted BChE nonapeptide 
with less than 10 ppm mass deviation. These product ions were traced successfully to 
identification of the precursor ion of the unadducted BChE nonapeptide with less than 1 ppm 
deviation from theoretical mass.
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Table 1
High mass accuracy evaluation of product ions from method validation (n=23).
AnalyteCode −2σ Window Mean Product Ion m/z (±σ ppm) +2σ Window
QCL: BChE
796 → 602 602.2519 602.2551 (±2.7 ppm) 602.2583
796 → 620 620.2508 620.2652 (±4.3 ppm) 620.2706
796 → 691 691.2982 691.3018 (±2.7 ppm) 691.3054
QCM: MeP-BChE
874 → 602 602.2536 602.2568 (±2.6 ppm) 602.2600
874 → 673 673.2903 673.2929 (±2.0 ppm) 673.2955
874 → 778 778.3328 778.3362 (±2.2 ppm) 778.3396
QCH: GB-BChE
916 → 602 602.2544 602.2564 (±1.6 ppm) 602.2584
916 → 673 673.2907 673.2935 (±2.1 ppm) 673.2963
916 → 778 778.3330 778.3360 (±2.0 ppm) 778.3390
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Table 3
Results of 80 blinded clinical specimens prepared to simulate an OPNA exposure.
Batch Total biomarkers Total identified/reportable range Score %
1 32 29/29 100
2 29 26/26 100
3 20 17/17 100
4 19 19/19 100
Total 100 91/91 100
*
Biomarkers below the threshold of 15 ng/mL were not included in this total.
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